188
Views
60
CrossRef citations to date
0
Altmetric
Review

Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs

, , , &
Pages 357-367 | Published online: 18 Jul 2011

References

  • Panel on Antiretroviral Guidelines for Adults and AdolescentsGuidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescentsDepartment of Health and Human Services11020111166 Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 2011 Feb 14.
  • McKinnonJEMellorsJWSwindellsSSimplification strategies to reduce antiretroviral drug exposure: progress and prospectsAntivir Ther200914111219320232
  • World Health OrganizationAntiretroviral Therapy For HIV Infection Adults And Adolescents: Recommendations for a public health approach 2010 revision. Available from: http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf.
  • HenryKBrundageRWellerDAkinseteOShetAComparison of generic zidovudine plus lamivudine (Cipla, Duovir) and the GlaxoSmithKline brand (Combivir) tabletsJ Acquir Immune Defic Syndr200435553715021319
  • VezinaHHenryKRavindranGDA randomized crossover study to determine bioequivalence of generic and brand name nevirapine, zidovudine, and lamivudine in HIV-negative women in IndiaJ Acquir Immune Defic Syndr200641213113616394842
  • ParientiJJBangsbergDRVerdonRGardnerEMBetter adherence with once-daily antiretroviral regimens: a meta-analysisClin Infect Dis200948448448819140758
  • MaitlandDJacksonAOsorioJSwitch Study TeamSwitching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapyHIV Med20089866767218631255
  • WrightDRodriguezAGodofskyEEfficacy and safety of 48 weeks of enfuvirtide 180 mg once-daily dosing versus 90 mg twice-daily dosing in HIV-infected patientsHIV Clin Trials200892738218474492
  • BoyleBAJayaweeraDWittMDRandomization to once-daily stavudine extended release/lamivudine/efavirenz versus a more frequent regimen improves adherence while maintaining viral suppressionHIV Clin Trials20089316417618547903
  • ZajdenvergRBadal-FaesenAndrade-VillanuevaJLopinavir/ritonavir (LPV/r) tablets administered once-(QD) or twice-daily (BID) with NRTIs in antiretroviral-experienced HIV-1 Infected subjects: results of a 48-week randomized trial (Study M06-802)5th IAS Conference on HIV pathogenesis, Treatment and PreventionCape Town, South Africa2009 Jul 19–22 Available from: http://www.ias2009.org/pag/Abstracts.aspx?AID=1249.
  • BangsbergDRRaglandKMonkAA single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed peopleAIDS201024182835284021045636
  • DeJesusEPozniakAGallantJImprovement in Fasting Lipids but Minimal Recovery of Limb Fat Were Seen 96 Weeks After Switching from Lamivudine/Zidovudine Plus Efavirenz to Fixed-Dose Efavirenz/Emtricitabine/Tenofovir DF in HIV-Infected Patients49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)September 12–15, 2009San Francisco, CA USA Poster# H-1572. Available from: http://www.hivandhepatitis.com/2009icr/icaac/pdfs/2_DeJesus.pdf. Accessed July 10, 2011.
  • AiroldiMZaccarelliMBisiLOne-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjectsPatient Prefer Adherence2010411512520517472
  • BaeJWGuyerWGrimmKAlticeFLMedication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and researchAIDS201125327929021239892
  • WilligJHAbromsSWestfallAOIncreased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapyAIDS200822151951196018784459
  • GardnerEMBurmanWJMaraviMEDavidsonAJSelective drug taking during combination antiretroviral therapy in an unselected clinic populationJ Acquir Immune Defic Syndr200540329430016249703
  • VoTTLedergerberBKeiserODurability and outcome of initial antiretroviral treatments received during 2000–2005 by patients in the Swiss HIV Cohort StudyJ Infect Dis2008197121685169418513155
  • DybulMChunTWYoderCShort-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parametersProc Natl Acad Sci U S A20019826151611516611734634
  • DybulMNies-KraskeEDewarRA proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infectionJ Infect Dis2004189111974198215143462
  • CohenCJColsonAESheble-HallAGMcLaughlinKAMorseGDPilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) studyHIV Clin Trials200781192317434845
  • CohenCColsonAPieroneG5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention The FOTO study: the 48 week extension to assess durability of the strategy of taking efavirenz, tenofovir and emtricitabine Five days On, Two days Off (FOTO) each week in virologically suppressed patients,Cape Town, South Africa2009 Jul 19–22 Ab#MOPEB063. Available from http://www.ias2009.org/pag/Abstracts.aspx?AID=3046.
  • DanelCMohRMingaATrivacan ANRS 1269 trial groupCD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trialLancet200636795271981198916782488
  • AnanworanichJGayet-AgeronALe BrazMStaccato Study GroupSwiss HIV Cohort Study. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trialLancet2006368953445946516890832
  • El-SadrWMLundgrenJDNeatonJDStrategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatmentN Engl J Med2006355222283229617135583
  • El-SadrWMGrundBNeuhausJRisk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trialAnn Intern Med2008149528929918765698
  • LundgrenJDBabikerAEl-SadrWInferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. Strategies for Management of Antiretroviral Therapy (SMART) Study GroupJ Infect Dis200819781145115518476293
  • EmerySNeuhausJAPhillipsANMajor clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART studyJ Infect Dis200819781133114418476292
  • KaufmannGRElziLWeberRInterruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and deathAIDS201125444145121206265
  • HavlirDVMarschnerIAHirschMSMaintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapyN Engl J Med199833918126112689791141
  • PialouxGRaffiFBrun-VezinetFTrilège (Agence Nationale de Recherches sur le SIDA 072) Study TeamA randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patientsN Engl J Med199833918126912769791142
  • OpravilMHirschelBLazzarinAA randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infectionJ Infect Dis200218591251126012001042
  • KatlamaCFenskeSGazzardBTRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence resultsHIV Med200342798612702127
  • MarkowitzMHill-ZabalaCLangJInduction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patientsJ Acquir Immune Defic Syndr200539325726415980684
  • MallolasJPichJPenarandaMInduction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone in naive HIV-1-infected adultsAIDS200822337738418195564
  • OpravilMBaumannDChaveJPLong-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudineAIDS200418162213221515577660
  • DelfraissyJFFlandrePDelaugerreCLopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patientsAIDS200822338539318195565
  • WilkinTJMcKinnonJEDiRienzoAGRegimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomesJ Infect Dis2009199686687119191590
  • BiermanWFvan AgtmaelMANijhuisMDannerSABoucherCAHIV monotherapy with ritonavir-boosted protease inhibitors: a systematic reviewAIDS200923327929119114854
  • ArribasJRPulidoFDelgadoRLopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study)J Acquir Immune Defic Syndr200540328028716249701
  • ArribasJRDelgadoRArranzAOK04 Study GroupLopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysisJ Acquir Immune Defic Syndr200951214715219349870
  • SwindellsSDiRienzoAGWilkinTRegimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppressionJAMA2006296780681416905786
  • KarlstromOJosephsonFSonnerborgAEarly virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapyJ Acquir Immune Defic Syndr200744441742217159658
  • ArribasJRHorbanAGerstoftJThe MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/mlAIDS201024222323020010070
  • KatlamaCValentinMAAlgarte-GeninGEfficacy of darunavir/ritonavir as single-drug maintenance therapy in patients with HIV-1 viral suppression: a randomized open-label noninferiority trial, MONOI-ANRS 136AIDS201024152365237420802297
  • GallantJEDeJesusEArribasJRStudy 934 GroupTenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIVN Engl J Med2006354325126016421366
  • SaxPETierneyCCollierACAIDS Clinical Trials Group Study A5202 TeamAbacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapyN Engl J Med2009361232230224019952143
  • MoyleGJSabinCACartledgeJRAVE (Randomized Abacavir versus Viread Evaluation) Group UKA randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophyAIDS200620162043205017053350
  • FisherMMoyleGJShahmaneshMSWEET (Simplification With Easier Emtricitabine Tenofovir) Group UKA randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individualsJ Acquir Immune Defic Syndr200951556256819561519
  • LaurentCBourgeoisAMpoudi-NgoléETolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in CameroonAIDS Res Hum Retroviruses200824339339918327976
  • HawkinsCAchenbachCFrydaWAntiretroviral durability and tolerability in HIV-infected adults living in urban KenyaJ Acquir Immune Defic Syndr200745330431017414931
  • MehtaUMaartensGIs it safe to switch between efavirenz and nevirapine in the event of toxicity?Lancet Infect Dis200771173373817961859
  • WatersLFisherMWinstonAA phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirineAIDS2011251657121099666
  • MallolasJPodzamczerDMilinkovicAATAZIP Study GroupEfficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP studyJ Acquir Immune Defic Syndr2009511293619390327
  • MillsAMNelsonMJayaweeraDOnce-daily darunavir/ritonavir vs lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysisAIDS200923131679168819487905
  • GatellJSalmon-CeronDLazzarinASWAN Study GroupEfficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week resultsClin Infect Dis200744111484149217479947
  • GrantPMPalmerSBendavidESwitch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of lifeClin Virol2009464305308
  • De CastroNBraunJCharreauIEASIER ANRS 138 study groupSwitch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trialClin Infect Dis20094981259126719757993
  • EronJJYoungBCooperDASwitch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trialsLancet2010375971239640720074791
  • MartínezELarrousseMLlibreJMSPIRAL Study GroupSubstitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL studyAIDS201024111697170720467288
  • VispoEBarreiroPMaidaISimplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trialHIV Clin Trials201011419720420974575
  • GardnerEMMaraviMERietmeijerCDavidsonAJBurmanWJThe association of adherence to antiretroviral therapy with healthcare utilization and costs for medical careAppl Health Econ Health Policy200862–314515519231907
  • MandaliaSMandaliaRLoGNPMS-HHC Steering GroupRising population cost for treating people living with HIV in the UK, 1997–2013PLoS One2010512e1567721209893
  • The ADAP Watch42011 Available from: http://www.nastad.org/Docs/Public/InFocus/201148_ADAP%20Watch%20update%20-%204.8.11.pdf. Accessed on 2011 May 13.
  • NachegaJBLeisegangRBishaiDAssociation of antiretroviral therapy adherence and health care costsAnn Intern Med20101521182520048268
  • GallantJEStaszewskiSPozniakEfficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients: a 3-year randomized trialJAMA2004292219120115249568
  • MilinkovicAMartinezELopezSThe impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patientsAntivir Ther200712340741517591031
  • Treatment Action CampaignTenofovir: an explanation of why we need TDF-dose combinations and the steps to bring them to the market in South Africa Available from: http://www.tac.org.za/community/node/2802; Accessed on 2011 May 13.
  • Department of Health, Republic of South AfricaThe South African Antiretroviral Treatment Guidelines 2010 Available from: http://www.doh.gov.za/docs/factsheets/guidelines/art.pdf. Accessed on 2001 May 13.
  • RosenSLongLFoxMSanneICost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral therapy regimens in South AfricaJ Acquir Immune Defic Syndr200848333434418545151